Patent portfolio covering multiple potency-enhanced CAR constructs and long-term cellular modulation technologies has been established, to improve the in vivo persistence and anti-tumor activity of dual-target CAR-T cells.

Holds patents related to scalable manufacturing processes for allogeneic universal CAR-T, enabling low-cost bulk production for industrialization.

A comprehensive patent matrix for in vivo targeted delivery has been built, encompassing proprietary technologies including targeted delivery proteins, engineered viral vectors, safe vector backbones, and AI-aided vector design, enabling precise in-situ CAR expression in vivo.

In August 2026, the Company’s first patent for the CD7/CD3 dual-target fusion protein and its applications was granted. It provides intellectual property protection to support pipeline advancement, IND filing and BD licensing collaborations.